Xvivo Perfusion AB (publ) (STO:XVIVO)
199.30
-1.70 (-0.85%)
Nov 5, 2026, 5:29 PM CET
Xvivo Perfusion AB Stock Forecast
Stock Price Forecast
According to 5 analysts polled by S&P Global, Xvivo Perfusion AB stock has a consensus rating of "Strong Buy" and an average price target of kr 304.00. The average 1-year stock price forecast is 52.53% higher than the current stock price, while the lowest is kr 260.00 (+30.46%) and the highest is kr 360.00 (+80.63%).
Price Target: kr 304.00 (+52.53%)
Analyst Consensus: Strong Buy
Price Target
ChartAnalyst Ratings
The average analyst rating for Xvivo Perfusion AB stock is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.
Recommendation Trends
| Rating | Apr '26 | May '26 | Jun '26 | Jul '26 | Aug '26 | Oct '26 |
|---|---|---|---|---|---|---|
| Strong Buy | 3 | 3 | 3 | 3 | 3 | 3 |
| Buy | 1 | 1 | 1 | 1 | 1 | 1 |
| Hold | 0 | 0 | 0 | 0 | 0 | 0 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 4 | 4 | 4 | 4 | 4 | 4 |
Financial Forecast
Revenue This Year
988.27M
from 812.17M
Increased by 21.68%
Revenue Next Year
1.20B
from 988.27M
Increased by 21.30%
EPS This Year
3.78
from 0.85
Increased by 343.54%
EPS Next Year
5.29
from 3.78
Increased by 40.20%
EPS and Forward PE are based on non-GAAP adjusted numbers. Financial currency is SEK.